Clinical parameters and treatment results in granulosa cell tumor of the ovary.
- Author:
Tae Joong KIM
1
;
Young Ah KOO
;
Chel Hun CHOI
;
Jeong Won LEE
;
Byoung Gie KIM
;
Je Ho LEE
;
Duk Soo BAE
Author Information
1. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ds123.bae@samsung.com
- Publication Type:Original Article
- Keywords:
Granulosa cell tumors;
Ovarian neoplasms;
Recurrence
- MeSH:
Adult;
Bleomycin;
Chemotherapy, Adjuvant;
Cisplatin;
Diagnosis;
Drug Therapy;
Etoposide;
Female;
Follow-Up Studies;
Granulosa Cell Tumor*;
Granulosa Cells*;
Humans;
Liver;
Lung;
Medical Records;
Neoplasm Metastasis;
Ovarian Neoplasms;
Ovary*;
Physical Examination;
Puberty, Precocious;
Recurrence;
Retrospective Studies;
Telephone;
Uterine Hemorrhage
- From:Korean Journal of Obstetrics and Gynecology
2006;49(1):122-130
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The purpose of this study was to evaluate the patients' characteristics and treatment results for 31 granulosa cell tumors (GCTs) of the ovary. METHODS: We retrospectively reviewed the medical records of 31 patients with GCT who received treatment from January, 1997 to April, 2005. They were grouped into 21 adult types, 4 juvenile types and 6 recurrent GCTs. Clinicopathological characteristics, treatment results and follow-up data were investigated from medical records and/or telephone surveys. RESULTS: In adult types, the median age of patients was 42 years (20 to 81 years). The most common present symptom was vaginal bleeding (10/21, 47.6%). All patients with adult type had FIGO stage I with median follow-up of 32 months (5-103 months). No recurrence developed in this group. In juvenile types, the median age was 8 years (2-14 years). Precocious puberty was presented in 2 of 4 (50%). Three had FIGO stage I and one had FIGO stage IIIa. Two patients were given adjuvant chemotherapy with bleomycin, etoposide, cisplatin (BEP) regimens for six cycles. No recurrence was found during median follow-up of 20.5 months (16-27 months). In recurrent GCTs, cytoreductive surgery and adjuvant chemotherapy were given to 5 patients. One patient, who had a disease with multiple liver and multiple lung metastases, was given palliative chemotherapy. All patients were alive, two were clinically in complete response. CONCLUSION: There was no recurrence in adult types and juvenile types, and no dead of disease in recurrent group. However, because of the propensities of GCT to recur years after initial diagnosis and to grow slowly with indolent course, prolonged surveillance with serial physical examination and imaging studies is reasonable.
